Hangzhou Tigermed, a China-based, pan-Asia clinical CRO, recently announced it paid $28 million to acquire a 98% stake in DreamCIS, a Korean clinical-stage CRO. Tigermed said it would finance the entire amount. Tigermed also formed a strategic agreement with DIAN Diagnostics to develop a central laboratory in China, along with data management, to improve the services it offers to its clients.
